3-EtO-PCP Stats & Data

Reasoning for harm-reduction additions, with sources: 1) Structural identity and synonyms verified via PiHKAL·info, which lists 3‑EtO‑PCP with SMILES CCOc1cccc(c1)C1(CCCCC1)N1CCCCC1 and links to PubChem CID 165361695; this supports naming, class, and structural inferences. 2) Primary community report describes 100 mg insufflated as very strong but tolerable with tolerance, and—critically—reports a delayed, excruciating intranasal/throat burn with soreness persisting days. This supports advising oral administration, cautious titration, and avoiding nasal ROA due to caustic irritation. The same post gives ROA-specific timing: ~10 min onset nasal, ~2–3 h peak, 6–7 h total, plus hazy stimulating afterglow. 3) PCP pages (Erowid) document ataxia, nystagmus, depersonalization, unpredictable behavior, seizures at high doses, and increased coma/respiratory risk when combined with CNS depressants; this justifies strong warnings against alcohol/GHB/benzodiazepines/opioids, as well as no-driving/operating machinery advice for at least the day of use. Cannabis is noted to have profound synergy with PCP, supporting placement under ‘caution’. 4) TripSit harm-reduction for PCP/3‑MeO‑PCP indicates that these are research chemicals with limited long-term data, advises avoiding redose early due to variable onset and steep dose-response in PCP analogues, and highlights potentiation by alcohol/benzodiazepines; this supports conservative titration and redose delays for 3‑EtO‑PCP by analogy. 5) Tramadol commonly lowers seizure threshold and has serotonergic activity; TripSit cautions against tramadol combinations broadly due to seizure/serotonin risks. Given dissociatives’ seizure risk at high doses, placing tramadol under ‘unsafe’ is justified. 6) Hydration and urinary health: heavy/frequent ketamine use is associated with cystitis-like urinary problems. While 3‑EtO‑PCP is not ketamine, advising users of dissociatives to monitor urinary symptoms and moderate frequency is prudent harm reduction extrapolated from dissociative literature. 7) Testing and misrepresentation: drug supply variability means mis-sales are plausible; promoting reagent-plus lab testing (FTIR/GC–MS) via drug checking services is appropriate. The cited Reddit post even includes GC–MS imagery for the sample tested; the Toronto Drug Checking Service is an example of a public lab resource. 8) Antipsychotics: Erowid notes severe hypotension when PCP is combined with chlorpromazine-like agents; users should not attempt self-treatment of agitation or confusion with such medications. 9) Mental health risks: PCP resources report psychotic episodes and aggressive or disinhibited behavior, supporting guidance to avoid if there is a history of psychosis/mania, ensure a calm setting, and have a sober sitter.